

Chronic obstructive pulmonary disease (COPD) Committee meeting

Date: 16/01/2018

Location: Manchester

Minutes: Draft

Committee members present:	
Andrew Molyneux (Chair)	Present for items 1–6
Katy Beckford	Present for items 1–6
Lauren Hogg	Present for items 1–6
Nick Hopkinson	Present for items 1–6
Klaus Irion	Present for items 1–2
Babu Naidu	Present for items 1–2
Karen O’Hara	Present for items 1–6
Tony Perkins	Present for items 1–6
Louise Restrick	Present for items 1–6
Ravijyot Saggu	Present for items 1–2
Karen Sennett	Present for items 1–6

In attendance:	
Jean Bennie Technical Analyst	Present for items 1-2
Rupert Franklin Guideline Commissioning Manager	Apologies
Marie Harrisingh Technical Analyst	Present for items 1–6
Les Hayes Business Analyst	Not required
Ben Johnson Senior Technical Analyst (HE)	Present for items 1–6
Yolanda Martinez Technical Analyst	Present for items 3 - 6
Anneka Patel Project Manager	Present for items 1–6
Joanne Perkin Senior Digital Editor	Not required
Joshua Pink Technical Adviser	Present for items 1–6
Gabriel Rogers Technical Adviser (HE)	Present for items 1–6

Committee minutes – COPD meeting 7

Sue Spiers Associate Director	Present for items 1–6
----------------------------------	-----------------------

Observing:

Kathryn Hopkins	Technical advisor	NICE
Catrin Austin	Technical analyst	NICE

Apologies:

Christopher Warburton	Committee member
Luisa Pettigrew	Committee member
Mohammed Al-Aloul	Co-opted committee member
Sarah MacFadyen	Committee member

1. Welcome and objectives for the meeting

The Chair welcomed the committee members and attendees to the seventh meeting on chronic obstructive pulmonary disease (COPD).

The Chair informed the committee of apologies as listed above.

The Chair asked everyone to verbally declare any new interests arising since the last meeting. The following new declarations were made:

Committee member	Declaration	Classification	Chairs action
Ravijyot Saggi	Nov 2017 'how to implement respiratory guidelines' aimed at primary care staff, jointly organised by Napp & TEVA. This will cover asthma & COPD, is non-promotional & I will not be taking any honoraria for them (it will instead be diverted to the BLF). One of the commentators for a	Specific personal non-financial Specific personal	Declare and participate Declare and

Committee minutes – COPD meeting 7

	<p>Drugs and Therapeutics Bulletin DTB article published 13.12.17 (vol 55, issue 12) on triple therapy - there were no monies received.</p> <p><i>'Single inhaler triple therapy for COPD'</i></p>	non-financial	participate
Tony Perkins	<p>Phone discussion with Sandoz pharmaceutical rep on Thursday 11.1.18. Discussed their product AirFluSal which is another brand of salmeterol / fluticasone inhaler, in preparation for a Devon formulary application meeting taking place on Wednesday 17.1.18</p> <p>Meeting with TEVA pharmaceutical rep 18th December – discuss the “IMPACT” (Improving the Management of Patients’ Asthma and COPD Treatment) service they offer to asses if this is a project Devon CCG want to engage with.</p> <p>January 2018 – no payment of any kind for either.</p>	<p>Specific, personal, non-financial</p> <p>Specific, personal, non-financial</p>	<p>Declare and participate</p> <p>Declare and participate</p>
Karen O’Hara	<p>Discussion regarding future clinical trial and patient/patient group potential for involvement in design for Patient recorded outcomes (PRO’s). December 1st. No monies or expenses received.</p>	Specific, personal, non-financial	Declare and participate
<p>The Chair and a senior member of the Developer’s team noted that the interests declared did not prevent the attendees from fully participating in the meeting.</p>			

Committee minutes – COPD meeting 7

2. Review question:

In people with stable COPD, what are the referral criteria (for example intact fissures) for lung surgery?

Nick Hopkinson, Committee member, gave an overview of procedures and materials used for lung surgery in people with stable COPD.

Jean Bennie (JB), technical analyst, presented the available clinical evidence for this review question for the committee's consideration. JB explained the next steps in the analysis to allow the review question to be answered and presented preliminary results. Ben Johnson (BJ), health economist, then provided an overview of the economic analyses conducted for this question.

The committee made six recommendations in this area.

3. Economic model update

Ben Johnson (BJ), health economist, provided an update of the economic model discussed at a previous meeting. BJ covered treatment pathways, adverse events, costs and health-related quality of life.

4. Review question:

In people with COPD, what factors (for example, viral infection) may cause an exacerbation?

Yolanda Martinez (YM), technical analyst, presented some of the available clinical evidence for this review question for the committee's consideration.

This review question will be revisited at a future meeting.

5. Summary of meeting

Joshua Pink, technical advisor, gave a brief summary of the discussions held and what is planned for the next meeting.

6. AOB

The chair thanked the committee for attending and confirmed the date of the next meeting (see below).

Next meeting:

Monday, 5th and Tuesday, 6th March, London NICE Offices (Derwent)